FDA approval brings first generic pergolide option for horses
Bottom line
Zygolide, a peppermint-flavored pergolide tablet from Dechra, entered the U.S. equine market after FDA approval as the first generic, bioequivalent alternative to Prascend for controlling clinical signs of pituitary pars intermedia dysfunction, or PPID, in horses. FDA announced the approval on January 9, 2026, and said Zygolide contains the same active ingredient as Prascend, which was first approved in 2011. Dechra positioned the product around practical administration features, including 360-degree scoring for half-tablet dosing and a flavor profile meant to support daily use in horses that need long-term therapy, while promotional materials in equine media framed the launch around helping owners “rediscover the partnership” and create “more happy moments together.” (fda.gov)
Why it matters: For equine veterinarians, the arrival of a generic pergolide option could ease one of the biggest friction points in PPID management: long-term adherence. PPID is common in older horses, and treatment often requires ongoing dose titration, monitoring of clinical signs, and endocrine testing. A lower-cost alternative with scored tablets may help some pet parents stay on therapy, especially in higher-dose cases, and Dechra’s owner-facing messaging clearly leans into quality-of-life and the horse-owner bond. The label also underscores familiar handling and safety issues, including not crushing tablets and using caution when splitting them because pergolide exposure can irritate people. (equimanagement.com)
What to watch: Watch for early field uptake, pricing pressure on pergolide therapy, and whether easier access to treatment pairs with broader PPID screening and monitoring efforts in 2026. It will also be worth watching whether Dechra’s lifestyle-oriented messaging translates into better refill persistence in a disease where daily administration is often the hard part. (equinefacilitydesign.com)
Dechra’s Zygolide has given equine practitioners a new option for managing pituitary pars intermedia dysfunction, with the FDA approving the product as the first generic drug for control of clinical signs associated with equine Cushing’s disease. The approval, announced by FDA on January 9, 2026, makes Zygolide the first bioequivalent alternative to brand-name Prascend in the U.S. horse market. (fda.gov)
That matters because pergolide has long been the standard medical therapy for PPID, a common endocrine disorder in aging horses. Prascend was first approved in 2011, and for years it has been the main labeled option for horses needing chronic treatment. At the same time, awareness of PPID has grown, along with interest in earlier diagnosis and closer monitoring, including point-of-care endocrine testing programs now being expanded through industry collaborations. (fda.gov)
Dechra announced the FDA approval on January 5, 2026, describing Zygolide as a first-to-market generic, peppermint-flavored pergolide tablet for horses with PPID. Product materials say the tablets are 1 mg, packaged in 60- and 160-count cartons, and scored to allow dosing to the nearest half tablet. The label recommends a starting dose of 2 mcg/kg once daily, with titration based on clinical response and endocrine testing, up to 4 mcg/kg daily. In the effectiveness data cited in Dechra’s product insert, 47 of 113 horses, or 41.6%, required a dose increase by Day 90, underscoring how often PPID therapy needs adjustment rather than simple one-and-done prescribing. (dechra-us.com)
Safety and handling details are likely to be as relevant as price. FDA and Dechra both note that pergolide tablets should not be crushed because of the potential for increased human exposure. The label also advises care when splitting tablets, warns that pregnant or lactating women should wear gloves during administration, and notes that inappetence is a known treatment issue. In the field study summarized in the product insert, decreased appetite occurred in 40 of 122 treated horses at one or more meals, with many cases arising during the first month of therapy. (fda.gov)
Industry reaction has focused on access and usability. In coverage sourced from Dechra’s announcement, Greg Schmid, DVM, Equine Medical Affairs Lead at Dechra, said the approval brings “a high-quality, cost-effective option” to market and highlighted the scored tablet design and peppermint flavor profile. That framing aligns with the company’s broader promotional push in equine media, including The Horse carousel materials emphasizing daily administration, the horse-owner bond, and lifestyle-oriented messages such as “Rediscover the partnership with Zyoglide®” and “Help your horse feel their best so you can enjoy more happy moments together.” (americanfarriers.com)
Why it matters: For veterinary professionals, Zygolide’s launch is less about a new mechanism than about what generic competition can do to improve compliance in a disease that depends on consistency. PPID cases often involve older horses with concurrent laminitis risk, body condition changes, coat abnormalities, and the need for repeat ACTH or other endocrine monitoring. If lower-cost pergolide reduces drop-off after diagnosis, practices may have a better chance of keeping horses on therapy long enough to titrate effectively and document response. That could be especially meaningful as more clinics adopt faster diagnostic workflows and identify PPID earlier. Dechra’s owner-facing campaign also suggests the company is trying to make adherence feel less like a technical medication task and more like part of preserving comfort, function, and the horse-human relationship. This is an inference based on the product’s generic positioning, Dechra’s affordability messaging, and the parallel expansion of PPID testing infrastructure. (americanfarriers.com)
There are still practical questions for the market to answer. Veterinarians will want to see how pricing compares in real-world dispensing channels, whether pet parents perceive the flavored, scored format as easier to use, and whether generic availability changes refill behavior over time. Clinicians will also need to reinforce that even with a more convenient tablet and consumer-friendly marketing, pergolide remains a prescription endocrine therapy that requires monitoring, dose adjustment, and careful handling. (dechra-us.com)
What to watch: The next signals will likely come from pharmacy pricing, prescribing patterns during the 2026 spring and summer PPID monitoring season, and any evidence that broader access to generic pergolide increases treatment persistence in horses diagnosed through expanding point-of-care testing programs. It will also be worth watching whether Dechra’s quality-of-life messaging gains traction with owners managing long-term PPID cases at home. (equinefacilitydesign.com)